NCT01349465View on ClinicalTrials.gov

3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

July 4, 2011

Primary Completion Date

January 5, 2016

Study Completion Date

January 5, 2016

Conditions
Hepatitis C
Interventions
DRUG

No treatment

No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.

Trial Locations (48)

Unknown

Bakersfield

La Jolla

Los Angeles

Jacksonville

Orlando

Chicago

New Orleans

Saint Paul

Tupelo

Chapel Hill

Cincinnati

San Antonio

Antwerp

Bruges

Brussels

Ghent

Leuven

Calgary

Ottawa

Toronto

Montreal

Montreal

Créteil

Grenoble

Lyon

Nice

Paris

Vandœuvre-lès-Nancy

Berlin

Cologne

Düsseldorf

Frankfurt A. M.

Freiburg im Breisgau

Hamburg

Hanover

Kiel

Würzburg

Bialystok

Bydgoszcz

Czeladź

Mysłowice

Warsaw

Moscow

Nizhny Novgorod

Saint Petersburg

Samara

Smolensk

Stavropol

All Listed Sponsors
lead

Janssen R&D Ireland

INDUSTRY

NCT01349465 - 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection | Biotech Hunter | Biotech Hunter